Scripscan:Twilight Litaka Pharma Ltd
Code:506985
cmp:24
Story:Mumbai-based Twilight Litaka Pharma is engaged in the business of manufacturing drug formulations and nutraceuticals.With the domestic pharma industry growing at 12% per annum, the company’s growth prospects over the next 2-3 years look attractive.Incorporated in 1974, the company was formerly called Li Taka Pharmaceuticals. It operationally merged with Care Unipac in October ’05 to form Twilight Litaka Pharma. It manufactures various therapeutic drugs in the form of tablets, capsules, liquids and ointments. The company has three manufacturing plants in Maharashtra, and one in Baddi, Himachal Pradesh.Contract manufacturing and loan licensing account for around 50% of the company’s revenues.It has contract manufacturing or loan licensing arrangements with companies like Novartis, Cipla, Wockhardt, Pfizer, Lupin and Serum. 35-40% of the company’s revenues come from domestic sales of its formulations, while the remaining 10-15% is contributed by export sales. The company sells over 120 formulations through its 1,000+ marketing personnel and sells its products in 35 countries. It also has an exclusive marketing arrangement with Cipla to market its brands across 10 states.It aims to achieve a turnover of Rs 500 crore by ’09-10. The proposed plant in Sikkim is likely to enjoy a 20-year excise tax benefit.The company is also trying to hedge against risks faced by the pharma industry.The company has been an outperformer in its sector and I see great chances of the scrip catching investors fancy going forward.Its my bet in the pharma sector,so folks go and buy it.
Search This Blog(Over 800 companies covered in the blog).
Archives : Old artciles
Friday, March 6, 2009
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
